Blog

  • iPhone users claim iOS 26 draining battery faster, Apple says ‘no problem’

    iPhone users claim iOS 26 draining battery faster, Apple says ‘no problem’

    Apple just released iOS 26 and is already facing a new wave of criticism. Customers are now reporting significant battery drain issues and expressing frustration over new features. Citing several users, a report said that the problems emerged almost immediately after the update was released. Users took to social media, particularly X, to voice their concerns about their phone’s power consumption.

    What iPhone users are saying about iOS 26 release

    One user claimed that their phone’s battery dropped from 100% to 79% in less than an hour, while another claimed their “battery health just fell down to 80%” since installing the new software. A third user noted a substantial drop to 50% battery life with less-than-usual morning usage.Some users claim that the stable version is buggy and takes time to render animations. One of the iOS 26 users in The Times of India team said that it takes some time for the phone to go back to the theme they chose.

    What Apple has to say

    Apple addressed the complaints in a support document, assuring customers that a temporary impact on battery life and thermal performance is “normal” after a major update. After “completing an update, particularly a major release, you might notice a temporary impact on battery life and thermal performance.”“This is normal, as your device needs time to complete the setup process in the background, including indexing data and files for search, downloading new assets and updating apps,” the company said.It also noted that some new features may require additional resources, which could cause a temporary impact on performance and battery life for some users.


    Continue Reading

  • Addition of Neoadjuvant TAR-200 to Cetrelimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

    Addition of Neoadjuvant TAR-200 to Cetrelimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

    By Matthew Stenger
    Posted: 9/16/2025 9:55:00 AM

    Last Updated: 9/16/2025 2:48:03 PM

    In an interim analysis of a phase II trial (SunRISe-4) reported in The Lancet Oncology, Necchi et al found that the addition of neoadjuvant TAR-200—a targeted releasing system that provides sustained delivery of gemcitabine within the bladder—to the PD-1 inhibitor cetrelimab resulted in a higher complete pathologic response rate compared with cetrelimab alone in patients with muscle-invasive bladder cancer who were ineligible for or declined neoadjuvant cisplatin-based chemotherapy.

    Study Details

    In the international open-label trial, 120 eligible patients with planned radical cystectomy were randomly assigned 5:3 between July 2022 and May 2024 to receive TAR-200 with gemcitabine at 225 mg plus cetrelimab at 360 mg every 21 days for four cycles (n = 79) or four cycles of cetrelimab at 360 mg every 21 days for four cycles (n = 41). The primary outcome measure was pathologic complete response in the efficacy-evaluable set; because not all patients had completed treatment at time of analysis, the efficacy-evaluable set was defined as all patients who had radical cystectomy or progressive disease or death before radical cystectomy.

    Key Findings

    Among patients in the efficacy-evaluable set, at a median follow-up of 23.5 weeks (interquartile range = 8.6–42.0 weeks), pathologic complete response was observed in 22 (42%, 95% confidence interval [CI] = 28%–56%) of 53 patients in the TAR-200/cetrelimab group vs 7 (23%, 95% CI = 10%–41%) of 31 in the cetrelimab group.

    Rates of pathologic overall response (downstaging to ≤ ypT1N0 at radical cystectomy) were 60% vs 35%.

    Treatment-related adverse events of any grade occurred in 72% of the TAR-200/cetrelimab group vs 44% of the cetrelimab group; grade ≥ 3 events occurred in 11% (most commonly hematuria, in 3%) vs 5% of patients. Serious treatment-related adverse events occurred in 11% vs 2% of patients. Treatment-related adverse events resulted in discontinuation of TAR-200 in 9% and cetrelimab in 8% in the TAR-200/cetrelimab group, with no discontinuations in the cetrelimab group. One treatment-related death was observed in the cetrelimab group (due to hyperglycemic, hyperosmolar, nonketotic syndrome).

    The investigators concluded: “Neoadjuvant TAR-200 plus cetrelimab showed a high [pathologic] complete response rate with a manageable safety profile. These results support continued investigation of TAR-200 in patients with muscle-invasive bladder cancer planned for radical cystectomy.”

    Andrea Necchi, MD, IRCCS, of San Raffaele Hospital, Milan, Italy, is the corresponding author for The Lancet Oncology article.

    Disclosure: The study was funded by Johnson & Johnson. For full disclosures of all study authors, visit thelancet.com.

    Continue Reading

  • Alzheimer Disease Risk Found Related to Timing of Hormone Replacement Therapy in Post-Menopausal Patients

    Alzheimer Disease Risk Found Related to Timing of Hormone Replacement Therapy in Post-Menopausal Patients

    A new meta-analysis research presented at the meeting of the American Neurological Association showed that timing of hormone replacement therapy for post-menopausal patients can affect risk of developing Alzheimer disease.1 The study found that beginning hormone replacement therapy within 5 years of menopause can lower risk of Alzheimer development by 20 to 32%, and beginning hormone therapy at age 65 or later can increase the risk by up to 38%.

    The meta-analysis included over 50 clinical trials and observational studies and compared women using hormone replacement therapy to a placebo/nontreatment group. The analysis looked at Alzheimer disease progression based on blood tests and brain imaging scans, studying the disease progression from initial mild cognitive impairment onward. The average age of individuals in these trials was 51. Overall, the analysis showed a 38% increase in risk of Alzheimer disease in women who began hormone replacement therapy at age 65 or older. The increased risk effect was particularly noticeable in women whose hormone therapy included progestin. Utilizing 45 observational studies, the meta-analysis found a 22% reduced risk of developing Alzheimer disease in women who started hormone replacement therapy nearer to the time of their menopause. From both groups of clinical and observational studies, investigators determined that individuals who started hormone replacement therapy within 5 years of beginning menopause had a 32% lower risk of developing Alzheimer disease.

    Researchers indicated that hormone replacement therapy may be useful because it can provide the benefits of estrogen when the natural estrogen levels are dropping in menopause. With sustained estrogen, which is considered to assist in neural communications, inflammation may decrease and protect against cell damage that can lead to Alzheimer disease. On the other hand, if individuals start an estrogen hormone replacement regimen 10 or more years after menopause, inflammation may increase or place stress on the brain’s blood vessels due to potential early signs of Alzheimer disease like reduced blood flow or clumping of proteins.

    “Starting hormone replacement therapy early may give the brain some protection, but if a woman already has Alzheimer’s or memory problems, hormone therapy won’t slow them down,” said FNU Vaibhav, MBBS, from Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, in a press release. “It’s like watering a plant: it helps when the plant is growing, but if it’s already wilting, it might be too late.”

    Hormone therapy in this context is utilized by women post-menopause, usually to treat symptoms like hot flashes and sleep disturbances. Common forms include administration of estrogen alone, a combination of estrogen and progestin (synthetic progesterone), or estrogen and a selective estrogen receptor modulator. Hormone replacement therapies are often administered in pill or patch form, and are currently used by around 5% of women in the US.2

    “The evidence isn’t strong enough to suggest hormone replacement therapy should be taken to prevent Alzheimer’s. However, if a woman is planning to use it for menopause symptoms, starting soon after menopause might give her brain some protection against Alzheimer’s disease later,” added Vaibhav. “She should talk to her doctor about stopping it after a few years to avoid raising her risk. And women should not start hormone replacement therapy in their 60s or 70s to protect their brain because it might do more harm than good.”

    References

    1. Timing of hormone replacement therapy may influence Alzheimer’s disease risk, study suggests. Press release. September 15, 2025. Accessed September 15, 2025. https://www.newswise.com/articles/timing-of-hormone-replacement-therapy-may-influence-alzheimer-s-disease-risk-study-suggests/?sc=dwhr&xy=5013482 

    2. Anderer S. Only about 5% of US women now use menopausal hormone therapy. JAMA. 2024;332(21):1779.

    Continue Reading

  • Marijuana use linked to increased risk of type 2 diabetes

    Marijuana use linked to increased risk of type 2 diabetes

    Weed might nearly quadruple a person’s risk of developing type 2 diabetes, a new study says.

    People who use cannabis have a 3.7 times greater risk of type 2 diabetes compared to the general population, researchers reported Monday at a meeting of the European Association for the Study of Diabetes in Vienna.

    “As cannabis becomes more widely available and socially accepted, and legalized in various jurisdictions, it is essential to understand its potential health risks,” said lead researcher Dr. Ibrahim Kamel, chief resident at Boston Medical Center.

    “These new sights from reliable real-world evidence highlight the importance of integrating diabetes risk awareness into substance use disorder treatment and counseling, as well as the need for health care professional to routinely talk to patients about cannabis use so that they can understand their overall diabetes risk and potential need for metabolic monitoring,” Kamel said in a news release.

    For the new study, researchers analyzed data pooled from 54 health care organizations across the U.S. and Europe.

    The team identified nearly 97,000 people between 18 and 50 years of age whose medical records reflected cannabis use ranging from occasional use to dependence.

    They compared the weed users to more than 4.1 healthy people with no record of substance use. Both groups were followed for five years.

    New cases of diabetes were significantly higher among cannabis users, with 1,937 cases compared to 518 in the healthy group.

    Statistics showed the marijuana users at nearly four times greater risk of type 2 diabetes, researchers reported.

    It might be that weed use affects a person’s blood sugar levels or insulin resistance, researchers said, or that people on cannabis eat in unhealthy ways that increase their diabetes risk.

    However, researchers noted that the study cannot prove that weed use causes diabetes, but only shows an association between the two.

    More research is needed to confirm these findings and better understand the relationship between cannabis and diabetes, including how weed might alter the effects of insulin in the body, researchers said.

    Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

    More information

    The U.S. Centers for Disease Control and Prevention has more on the health effects of marijuana.

    Copyright © 2025 HealthDay. All rights reserved.

    Continue Reading

  • AI-powered CRISPR could lead to faster gene therapies, Stanford Medicine study finds

    AI-powered CRISPR could lead to faster gene therapies, Stanford Medicine study finds

    Yilong Zhou, a visiting undergraduate student from Tsinghua University, used CRISPR-GPT to successfully active genes in A375 melanoma cancer cells as part of his research into better understanding why cancer immunotherapy sometimes fails.

    Zhou typed his question into CRISPR-GPT’s text box: “I plan to do a CRISPR activate in a culture of human lung cells, what method should I use?”

    CRISPR-GPT responded like an experienced lab mate advising a new researcher. It drafted an experimental design and, at each step, explained its “thought” process, describing why the various steps were important.

    “I could simply ask questions when I didn’t understand something, and it would explain or adjust the design to help me understand,” Zhou said. “Using CRISPR-GPT felt less like a tool and more like an ever-available lab partner.”

    As an early-career scientist, Zhou had designed only a handful of CRISPR experiments prior to using CRISPR-GPT. In this experiment, it took him one attempt to get it right — a rarity for most scientists.

    In the past, Zhou was constantly worrying about making mistakes and double-checking his designs.

    Reducing error and increasing accessibility

    CRISPR-GPT can toggle between three modes: beginner, expert and Q&A. The beginner mode functions as a tool and a teacher, providing an answer and explanation for each recommendation. Expert mode is more of an equal partner, working with advanced scientists to tackle complex problems without providing additional context. Any researcher can use the Q&A function to directly address specific questions.

    It’s also useful for sharing knowledge and collaborating with other labs, Cong said. CRISPR-GPT provides a more detailed and holistic response than what’s generally gleaned from a scientific manuscript and responds to repetitive inquires in a snap.

    CRISPR-GPT can also check researchers’ work and apply experimental frameworks to new diseases the researchers may not be thinking about.

    “People in my lab have been finding this tool very helpful,” Cong said. “The decisions are ultimately made by human scientists, but it just makes that whole process — from experiment design to execution — super simple.”

    Editing responsibly and future expansion

    While the technology is promising for accelerating therapeutic research, there are still some safety concerns to address before pushing CRISPR-GPT more broadly.

    Cong and his team have already incorporated safeguards to protect the AI tool from irresponsible uses. For instance, if the AI receives a request to assist with an unethical activity, such as editing a virus or human embryo, CRISPR-GPT will issue a warning to the user and respond with an error message, effectively halting the interaction. Cong also plans to bring the technology to government agencies, such as the National Institute of Standards and Technology, to ensure ethical use and sound biosecurity.

    In the future, the tool may serve as a blueprint for training AI to execute specific biological tasks outside of gene editing. From developing new lines of stem cells as experimental models, to deciphering molecular pathways involved in heart diseases, Cong hopes to expand the technology to other disciplines building a range of AI agents to aid in genomic discovery. To that end, he and his team developed the Agent4Genomics website, where they host a range of related AI tools for scientists to use and explore.

    Researchers at Google DeepMind, Princeton University and the University of California, Berkeley contributed to this study.

    Funding for this research came from the National Institute of Health (grants 1R35HG011316 and 1R01GM1416), the Donald and Delia Baxter Foundation Faculty Scholar Award, the Weintz Family Foundation, and the National Science Foundation.

    Continue Reading

  • Initial Conditions For Tidal Synchronisation Of A Planet By Its Moon

    Initial Conditions For Tidal Synchronisation Of A Planet By Its Moon

    Deep Space Climate Observatory (DSCOVR) satellite’s EPIC maintains a constant view of the fully illuminated Earth as it rotates, providing scientific observations of ozone, vegetation, cloud height and aerosols in the atmosphere. About twice a year the camera captures the Moon and Earth together as the orbit of DSCOVR crosses the orbital plane of the Moon. These images were taken between 3:50 p.m. and 8:45 p.m. EDT showing the moon moving over the Pacific Ocean near North America. The North Pole is in the upper left corner of the image. It is in the original orientation as taken by the spacecraft. larger image

    Moons tidally interact with their host planets and stars. A close moon is quickly synchronised by the planet, or becomes captured in a higher spin-orbit resonance.

    However, the planet requires much more time to significantly alter its rotation rate under the influence of moon-generated tides. The situation becomes more complex for close-in planets, as star-generated tides come into play and compete with the moon-generated tides. Synchronisation of the planet by its moon changes the tidal dynamics of the entire star-planet-moon system and can lead to long-term stable configurations.

    In this paper, we demonstrate that a certain initial condition must be met for this to occur. Based on the angular-momentum conservation, the derived condition is universal and bears no dependence upon the planet’s internal structure or tidal dissipation model.

    It is applicable to dwindling systems as well as tidally expanding orbits, and to the cases of initially retrograde motion. We present calculations for specific planet-moon systems (Earth and the Moon; Neptune and Triton; Venus and its hypothetical presently-extinct moon Neith; Mars, Phobos, and Deimos; Pluto and Charon), to constrain the dynamically plausible formation and evolution scenarios.

    Among other things, our analysis prompts the question of whether Pluto and Charon evolved into their current state from an initially more compact configuration (as is commonly assumed) or from a wider orbit — a topic to be discussed at length elsewhere. Our results are equally applicable to exoplanets. For example, if asynchronous close-in exoplanets are detected, the possibility of tidal synchronisation by an exomoon should be considered.

    Valeri V. Makarov, Michael Efroimsky

    Subjects: Earth and Planetary Astrophysics (astro-ph.EP)
    Cite as: arXiv:2509.09858 [astro-ph.EP] (or arXiv:2509.09858v1 [astro-ph.EP] for this version)
    https://doi.org/10.48550/arXiv.2509.09858
    Focus to learn more
    Journal reference: Universe 2025, 11(9), 309
    Related DOI:
    https://doi.org/10.3390/universe11090309
    Focus to learn more
    Submission history
    From: Michael Efroimsky
    [v1] Thu, 11 Sep 2025 21:09:01 UTC (174 KB)
    https://arxiv.org/abs/2509.09858
    Astrobiology,

    Explorers Club Fellow, ex-NASA Space Station Payload manager/space biologist, Away Teams, Journalist, Lapsed climber, Synaesthete, Na’Vi-Jedi-Freman-Buddhist-mix, ASL, Devon Island and Everest Base Camp veteran, (he/him) 🖖🏻

    Continue Reading

  • Mohun Bagan lose opener to Ahal FC

    Mohun Bagan lose opener to Ahal FC

    Mohun Bagan Super Giant endured a disappointing start to their AFC Champions League Two 2025-26 campaign, losing 1-0 to Turkmenistan’s Ahal FC at the Salt Lake Stadium on Tuesday.

    An 83rd-minute strike from Enwer Annayev sealed the win for the visitors, leaving the Indian football club empty-handed from its Group C opener.

    Ahal signalled their intent from the outset. Suleyman Mirzoyev found space in just the second minute but skewed wide, while Magtymberdi Berenov and Mirzoyev continued to stretch the Mohun Bagan defence.

    The Mariners grew into the contest around the 13th minute when Liston Colaco and Sahal Abdul Samad had efforts blocked in quick succession.

    Jason Cummings spurned their best first-half chance, blasting over from inside the box after a neat exchange with Samad.

    Mohun Bagan keeper Vishal Kaith was the busier of the two goalkeepers after the restart, denying Berenov twice and producing a big save in the 69th minute when Mirzoyev squared for Berenov at the near post.

    Kaith was again at full stretch in the 80th minute to keep out Mirzoyev’s header. At the other end, Samad came close from a counter but dragged his shot wide.

    Just when the match seemed destined for a stalemate, Annayev’s finish sealed the points for the visitors.

    Continue Reading

  • Apple’s opening gambit? Lead from behind – Apple Must

    Apple’s opening gambit? Lead from behind – Apple Must

    Aesop tells us that once upon a time there was a boastful hare that raced a tortoise, got ahead, took a nap, overslept, and lost the race. Just like Apple, the tortoise was slow, steady, and consistent – and just like Apple, the chelonian, eventually took the prize.

    Stop to think about it and Apple has often been the tortoise in the tech race.

    Sure, it made the first personal computer, but it didn’t make the first music player, did not make the first phone, and arguably didn’t make the first smartwatch. Despite which once it entered all of those markets it quickly climbed to the top.

    Now it’s going to do it again with AI.

    Think about what we saw last week: vapor-cooled smartphones operating delivering MacBook Pro performance in a tiny frame; powerful new A19 processors, AI-boosted power management; new networking chips all coupled with operating system enhancements to exploit all this new power.

    Apple has made numerous references to the potential in its products to deliver AI experiences, and as we look at its secure, private by design systems it’s impossible to reject its claims. Partly because as yet we can’t test them.

    But it’s all infrastructure. And as we wait to see the extent to which Apple is able to exploit these new designs in new Macs, iPads and M-series chips based on the A19 hardware, one thing we can be completely certain about is that, given a bigger heat sync, those Mac chips will deliver more power, more performance, at lower energy requirements than anyone else, making these systems enormously powerful even as Apple ships Apple Intelligence 2.0.

    The tortoise will defeat the hare

    Combined with the partnerships the company is putting in place with third party AI providers, and in contrast to other platforms, Apple is, like the tortoise, slowly and steadily building a user ecosystem to support AI, even as more and more people navigate to its platforms.

    While it’s true developoing Apple intelligence has taken a lot longer than the company originally planned, it continues to slowly, steadily, put the infrastructiure in place, and now offers a viable AI platform across mobile, smartphone, computer, television and beyond – and that platform is simply faster than what anyone else can provide.

    As I see it, over the next 12-months Apple will make its move, and once it does we’ll forget that anyone ever thought it had fallen behind in AI.

    You can follow me on social media! Join me on BlueSky,  LinkedIn, and Mastodon.

    Continue Reading

  • Webtoon Shares Soar Disney Digital Comics Partnership

    Webtoon Shares Soar Disney Digital Comics Partnership

    Webtoon Entertainment saw its stock price soar on Tuesday on news it has expanded a partnership with Walt Disney, which in turn has acquired a 2 percent stake in the media company behind the mainstream embrace of webcomics.

    As the digital comics company makes inroads in Hollywood, Webtoon and Disney will build and operate a new digital comics platform to bring 35,000 comics from Marvel, Star Wars, Disney, Pixar and 20th Century Studios under one service. And Disney+ subscribers will have access to a selection of content from the new platform.

    As part of the deal, Walt Disney has agreed to acquire a 2 percent stake in Webtoon Entertainment for an unspecified price. Unveiling the agreement to develop the digital comic platform and the proposed share stake purchase led shares of Webtoon to soar by $5.57, or just over 37 percent, to $20.62 in mid-day trading on the NASDAQ Exchange.

    Webtoon, which has around 155 million monthly active users, and Disney previously struck a multi-year partnership that features about 100 reformatted classics and all-new original series.

    “By uniting our unparalleled collection of comics across Marvel, Star Wars, Disney, Pixar and 20th Century Studios into a single digital platform, we’re giving fans unprecedented access to the adventures they love — all in one place,” Josh D’Amaro, chairman of Disney Experiences, said in a statement.

    With a ticker symbol of WBTN, Webtoon, backed by South Korean tech titan Naver, produces content that comes out in installments or “episodes.” Digital comics are embraced in Asia and very popular in North America. But comics are still considered the domain of traditional floppy books dominated by DC and Marvel.

    Webtoon is changing that market by focusing on the teenage demo, non-superhero genres, and by making it easy for anyone to create content. Among its popular titles are Lore Olympus and Tower of God.

    “With a new platform that will combine our product and technical expertise with Disney’s full comic catalog, we’re giving new and longtime fans all over the world a new way to discover these legendary characters and stories,” said Junkoo Kim, Webtoon founder and CEO. “Disney’s extraordinary storytelling legacy is second to none, and we’re honored to work with them to build the future of digital comics. This is a powerful next step for our growing global business and a strong foundation for even greater collaboration with Disney in the years ahead.”

    Continue Reading

  • Cybersecurity provider Netskope boosts IPO range

    Cybersecurity provider Netskope boosts IPO range

    Sanjay Beri, chief executive officer and founder of Netskope Inc., listens during a Bloomberg West television interview in San Francisco, California.

    David Paul Morris | Bloomberg | Getty Images

    Netskope is targeting a $7.3 billion valuation in its upcoming initial public offering, after lifting its planned price range.

    The cybersecurity company said it plans to sell 47.8 million shares at between $17 and $19 apiece. The deal would raise as much as $908 million at the top end.

    That’s up from a previous range of $15 to $17 a share the company revealed in a filing last week, at a $6.5 billion valuation.

    The cloud security company revealed plans to go public on the Nasdaq in a filing last month. Its planned debut comes amid an influx of big cybersecurity deals and during a resurgence in IPO activity after soaring inflation and interest rates squashed appetite for tech deals.

    Cybersecurity deals have topped the list of this year’s biggest tech acquisitions.

    The frenzy was highlighted by Google’s $32 billion acquisition of Israeli cloud security startup Wiz in March. Palo Alto announced this summer that it’s buying identity security company CyberArk for $25 billion. Thoma Bravo-backed SailPoint went public in February.

    As tariff headwinds eased, companies increasingly looked to the public markets.

    Design platform Figma and Circle more than doubled in their recent market debuts. CoreWeave has more than tripled since its IPO.

    After putting the brakes on IPO plans earlier this year with President Donald Trump’s tariff plans roiling global markets, Klarna jumped 15% in its NYSE debut last week. Ticket reseller StubHub is also planning a debut this month.

    Netskope will debut under the ticker symbol “NTSK.” The company reported a net loss of $170 million during the first half of the year in its prospectus filing.

    The California-based company, founded in 2012, operates in the cloud access security space, helping firms protect against cyber threats. Netskope named Palo Alto Networks, Cisco and Broadcom among its competitors in its IPO filing.

    Continue Reading